Reported to be the most frequent type of interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF) commonly makes itself apparent in patients seventy and older. Due to its vague presentation earlier in life, IPF is usually classified as a late-stage illness. This is because as IPF progresses, even in the early, undetected stages, can cause irreversible damage to the pulmonary tissue, restrictive lung disease, and hypoxia. Without a lung transplant, the disease can be fatal, causing acute pulmonary failure in patients two to four years (on average) after diagnosis.
While risk factors of IPF include smoking, metal/wood dust inhalation, and other genetic factors, incidence can also rise with the patient’s age, with higher frequency in men than women.1,2 According to reports, most individuals with idiopathic pulmonary fibrosis experience progressive, often longer-than-six-month development of dyspnea and/or non-productive cough. In many situations, it takes between one and two years from the onset of symptoms to the diagnosis. For the diagnosis of idiopathic pulmonary fibrosis, results using high-resolution computed tomography (HRCT) are far more sensitive and specific.
Biopharma companies have initiated over 300 ongoing clinical trials in IPF since 2014, with the Asia-Pacific region involved in over 30% of the trials. Learn about the incidence, distribution, and possible control of IPF in the Asia Pacific region, in addition to the standard of care, current trial landscape, and more when you access this detailed report.